Ciprofloxacin HCI, is a highly popular antibacterial agent in the third world countries including India. Many companies are engaged in manufacturing and marketing the brands, purchasing the basic drug from the core suppliers. Often these brands vary in cost and companies usually claim superiority of their product to justify the higher price. There is a possibility that products containing same amount of basic drug are therapeutically equivalent. So, if it can be proved that the different brands are therapeutically equivalent, they can be substituted for each in prescription and patient can be take advantage of an economic dosage regimen. This could be achieved by assessing physicochemical equivalence of different brands of the drug. Assessment may include the evaluation of uniformity of weight, friability, hardness, disintegration and dissolution tests as well as chemical assay of tablets.

PDF